Dilution profile // every instrument, one screen, from SEC filings

ABEONA THERAPEUTICS INC. (ABEO)

CIK 318306 · all EDGAR filings →

Overall dilution risk
HIGHworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
HIGHS-3/A on file 2024-06-17
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
LOWwarrants = 10% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
HIGH+130% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
a reverse-split-sized cliff is in this window; read the chart
Cash need
LOW~26.5 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2020-08-032026-05-08

Latest: 57.0M shares as of May 8, 2026 (10-Q). Share count fell from 146.9M to 6.0M between May 3, 2022 and Aug 1, 2022, a pattern consistent with a reverse split (roughly 1-for-25); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

TrancheWarrantsExercise priceTermNotes
Twenty Twenty Two Private Placement Offering5.8M$4.75
Two Thousand Twenty Three Pre Funded Warrants2.6M$0.0001
Two Thousand Twenty Four Pre Funded Warrants2.5M$0.0001
Twenty Twenty One Public Offering Warrants1.8M$9.75
Twenty Twenty Four Loan Agreement589,681$4.07
Twenty Twenty Four Loan Agreement One16,474$6.07

Tranches exactly as the company dimensioned them in its 10-Q filed May 13, 2026. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Warrants outstanding: 5.8M underlying shares, as reported Dec 31, 2025 (10-K).

Reported exercise price: $4.0299 (aggregate figure as tagged; individual tranches vary).

Balance-sheet fair value of warrants: $1.1M as of Aug 31, 2025.

Rough fully diluted estimate: 62.8M = 57.0M O/S + 5.8M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed May 13, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding57.0MMay 8, 2026
+ Twenty Twenty Two Private Placement Offering (if exercised)5.8MMar 31, 2026
+ Two Thousand Twenty Three Pre Funded Warrants (if exercised)2.6MMar 31, 2026
+ Two Thousand Twenty Four Pre Funded Warrants (if exercised)2.5MMar 31, 2026
+ Twenty Twenty One Public Offering Warrants (if exercised)1.8MMar 31, 2026
+ Twenty Twenty Four Loan Agreement (if exercised)589,681Mar 31, 2026
+ Twenty Twenty Four Loan Agreement One (if exercised)16,474Mar 31, 2026
Fully diluted estimate70.3M+23.3% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Jun 12, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 0 executed · 0 registered.

UPDATEJul 10, 2026Prospectus update — often a resale registration, not necessarily new capital424B3
EXECUTEDJun 21, 2024Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EFFECTIVEJun 20, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDJun 17, 2024S-3/A registration — capacity to sell shares, not a sale yetS-3/A
REGISTEREDJun 12, 2024S-3 registration — capacity to sell shares, not a sale yetS-3
EXECUTEDMay 3, 2024Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDJul 3, 2023Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDJun 7, 2023Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDMar 29, 2023Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EFFECTIVEDec 12, 2022SEC declared a registration effective — selling can beginEFFECT
REGISTEREDDec 1, 2022S-3 registration — capacity to sell shares, not a sale yetS-3
EXECUTEDNov 3, 2022Unregistered share sale disclosed (8-K item 3.02)8-K

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full ABEO workspace